Ligand to Participate in Two Upcoming Investor Conferences
May 22 2017 - 9:00AM
Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
announces that company executives are scheduled to participate in
the following upcoming investor conferences:
- 14th Annual Craig-Hallum Institutional
Investor Conference in Minneapolis. Conference takes place on
Wednesday, May 31, 2017 with one-on-one meetings only. John
Higgins, CEO; Matt Foehr, President and COO; and Matt Korenberg,
CFO, will attend for Ligand.
- Jefferies Healthcare Conference in New
York City. Presentation takes place on Thursday, June 8, 2017 at
4:00 p.m. Eastern time (1:00 p.m. Pacific time). John Higgins, CEO;
Matt Foehr, President and COO; and Matt Korenberg, CFO, will attend
for Ligand.
A live webcast of the presentation will be available on Ligand’s
website at www.ligand.com. A replay of the presentation will be
archived on the website for 30 days.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or
acquiring technologies that help pharmaceutical companies discover
and develop medicines. Our business model creates value for
stockholders by providing a diversified portfolio of biotech and
pharmaceutical product revenue streams that are supported by an
efficient and low corporate cost structure. Our goal is to offer
investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk
business than a typical biotech company. Our business model is
based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering. We partner with
other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s
Captisol® platform technology is a patent-protected, chemically
modified cyclodextrin with a structure designed to optimize the
solubility and stability of drugs. OmniAb® is a patent-protected
transgenic animal platform used in the discovery of fully human
mono- and bispecific therapeutic antibodies. Ligand has established
multiple alliances, licenses and other business relationships with
the world's leading pharmaceutical companies including Novartis,
Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter
International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170522005420/en/
Contacts:Ligand Pharmaceuticals IncorporatedTodd
Pettingillinvestors@ligand.com(858) 550-7500@Ligand_LGNDorLHABruce
Vossbvoss@lhai.com(310) 691-7100
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Sep 2023 to Sep 2024